Janssen Korea, Ltd.

Clinical trials sponsored by Janssen Korea, Ltd., explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

A subsidiary of Johnson & Johnson, involved in pharmaceutical sales and research in Korea.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Bladder cancer surgery: what happens after the bladder is removed? Results expected Nov 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet recruiting 1 Completed 1

New nasal spray could help those with stubborn depression

Disease control Completed

This study tests esketamine nasal spray in 47 Korean adults with treatment-resistant depression (depression that hasn't improved with other treatments). Participants will use the spray themselves twice a week for 4 weeks. The main goal is to see if depressive symptoms improve, me…

Phase 4 • Sponsor: Janssen Korea, Ltd., Korea • Aim: Disease control

Last updated Aug 05, 2026 00:00 UTC

Janssen Korea, Ltd.

Upcoming readouts

New nasal spray could help those with stubborn depression